机构:[1]Faculty of Medicine, Epithelial Cell Biology Research Center, School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, People’s Republic of China[2]Key Laboratory for Regenerative Medicine of the Ministry of Education of China, Faculty of Medicine, School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, People’s Republic of China[3]School of Biomedical Sciences Core Laboratory, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, People’s Republic of China[4]Sichuan University-The Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Chengdu, People’s Republic of China
Mutations of cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis, the most common life-limiting recessive genetic disease among Caucasians. CFTR mutations have also been linked to increased risk of various cancers but remained controversial for a long time. Recent studies have begun to reveal that CFTR is not merely an ion channel but also an important regulator of cancer development and progression with multiple signaling pathways identified. In this review, we will first present clinical findings showing the correlation of genetic mutations or aberrant expression of CFTR with cancer incidence in multiple cancers. We will then focus on the roles of CFTR in fundamental cellular processes including transformation, survival, proliferation, migration, invasion and epithelial-mesenchymal transition in cancer cells, highlighting the signaling pathways involved. Finally, the association of CFTR expression levels with patient prognosis, and the potential of CFTR as a cancer prognosis indicator in human malignancies will be discussed.
基金:
The work was supported in parts by National 973 Project
(2013CB967404, 2013CB967401, 2013CB967403), Research Grant
Council of Hong Kong (CUHK 466413, CUHK14119516), National
Natural Science Foundation of China (81571390), the Focused Investment Scheme of the Chinese University of Hong Kong and L.K.S
Foundation
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类|2 区生物
小类|2 区生化与分子生物学3 区细胞生物学
最新[2023]版:
大类|2 区生物学
小类|2 区生化与分子生物学2 区细胞生物学
第一作者:
第一作者机构:[1]Faculty of Medicine, Epithelial Cell Biology Research Center, School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, People’s Republic of China[2]Key Laboratory for Regenerative Medicine of the Ministry of Education of China, Faculty of Medicine, School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, People’s Republic of China[3]School of Biomedical Sciences Core Laboratory, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, People’s Republic of China
通讯作者:
通讯机构:[1]Faculty of Medicine, Epithelial Cell Biology Research Center, School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, People’s Republic of China[2]Key Laboratory for Regenerative Medicine of the Ministry of Education of China, Faculty of Medicine, School of Biomedical Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, People’s Republic of China[3]School of Biomedical Sciences Core Laboratory, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, People’s Republic of China[4]Sichuan University-The Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Chengdu, People’s Republic of China
推荐引用方式(GB/T 7714):
Zhang Jieting,Wang Yan,Jiang Xiaohua,et al.Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer.[J].Cellular and molecular life sciences : CMLS.2018,75(10):1737-1756.doi:10.1007/s00018-018-2755-6.
APA:
Zhang Jieting,Wang Yan,Jiang Xiaohua&Chan Hsiao Chang.(2018).Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer..Cellular and molecular life sciences : CMLS,75,(10)
MLA:
Zhang Jieting,et al."Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer.".Cellular and molecular life sciences : CMLS 75..10(2018):1737-1756